FDA Approves Nivolumab, Hyaluronidase-nvhy for Subcutaneous Injection | GU Oncology Now
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Related Articles
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Support Services
The Lymphoma Research Foundation (LRF) offers a wide range of support services, for people with lymphoma and their loved ones.
SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
SurgOnc Today® – Society of Surgical Oncology
SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their…
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Interactive Maps
Tip: Hover on a state to see its rate (and 95% C.I.). Click a state to show its counties.
Anemia During Ruxolitinib Treatment Is Associated With Worse Outcomes for Patients With MF | Blood Cancers Today
In the real-world setting, patients with MF and anemia who were treated with ruxolitinib had poorer survival outcomes than patients without anemia.
Oncology Center of Excellence Guidance Documents
Recently added guidance documents regarding oncology and malignant hematology
